Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

2.50
Hdl Handle:
http://hdl.handle.net/10541/74886
Title:
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Pippen, John; Elledge, Richard M; Mauriac, Louis; Vergote, Ignace; Jones, Stephen E; Come, Steven E; Osborne, C Kent; Robertson, John F R
Abstract:
BACKGROUND: Fulvestrant is an estrogen receptor antagonist with no agonist effects. In the second-line treatment of advanced breast carcinoma, fulvestrant was shown previously to be as effective as the third-generation aromatase inhibitor, anastrozole, in terms of time to disease progression and objective response rates. The authors reported the overall survival results from these studies. METHODS: A prospectively planned, combined, overall survival analysis was performed, including data from two Phase III trials that compared the efficacy and tolerability of fulvestrant (250 mg monthly; n = 428) with anastrozole (1 mg daily; n = 423) in the treatment of postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment. RESULTS: At an extended median follow-up of 27.0 months (range, 0-66.9 months), 319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients in the anastrozole group had died. Prolonged survival was observed with both drugs, with 10-20% of patients still alive > 5 years after randomization. The median overall survival was similar between treatments, being 27.4 months and 27.7 months in fulvestrant and anastrozole-treated patients, respectively (hazards ratio, 0.98; 95% confidence interval, 0.84-1.15; P = 0.809). Fulvestrant continued to be well tolerated, and was associated with a significantly lower incidence of joint disorders compared with anastrozole (P = 0.0234). CONCLUSIONS: The current analysis showed that fulvestrant was similar to anastrozole with respect to overall survival in the second-line treatment of postmenopausal women with advanced breast carcinoma.
Affiliation:
Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom. maria.parker@christie-tr.nwest.nhs.uk
Citation:
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. 2005, 104 (2):236-9 Cancer
Journal:
Cancer
Issue Date:
15-Jul-2005
URI:
http://hdl.handle.net/10541/74886
DOI:
10.1002/cncr.21163
PubMed ID:
15937908
Type:
Article
Language:
en
ISSN:
0008-543X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorPippen, John-
dc.contributor.authorElledge, Richard M-
dc.contributor.authorMauriac, Louis-
dc.contributor.authorVergote, Ignace-
dc.contributor.authorJones, Stephen E-
dc.contributor.authorCome, Steven E-
dc.contributor.authorOsborne, C Kent-
dc.contributor.authorRobertson, John F R-
dc.date.accessioned2009-07-22T10:32:46Z-
dc.date.available2009-07-22T10:32:46Z-
dc.date.issued2005-07-15-
dc.identifier.citationFulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. 2005, 104 (2):236-9 Canceren
dc.identifier.issn0008-543X-
dc.identifier.pmid15937908-
dc.identifier.doi10.1002/cncr.21163-
dc.identifier.urihttp://hdl.handle.net/10541/74886-
dc.description.abstractBACKGROUND: Fulvestrant is an estrogen receptor antagonist with no agonist effects. In the second-line treatment of advanced breast carcinoma, fulvestrant was shown previously to be as effective as the third-generation aromatase inhibitor, anastrozole, in terms of time to disease progression and objective response rates. The authors reported the overall survival results from these studies. METHODS: A prospectively planned, combined, overall survival analysis was performed, including data from two Phase III trials that compared the efficacy and tolerability of fulvestrant (250 mg monthly; n = 428) with anastrozole (1 mg daily; n = 423) in the treatment of postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment. RESULTS: At an extended median follow-up of 27.0 months (range, 0-66.9 months), 319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients in the anastrozole group had died. Prolonged survival was observed with both drugs, with 10-20% of patients still alive > 5 years after randomization. The median overall survival was similar between treatments, being 27.4 months and 27.7 months in fulvestrant and anastrozole-treated patients, respectively (hazards ratio, 0.98; 95% confidence interval, 0.84-1.15; P = 0.809). Fulvestrant continued to be well tolerated, and was associated with a significantly lower incidence of joint disorders compared with anastrozole (P = 0.0234). CONCLUSIONS: The current analysis showed that fulvestrant was similar to anastrozole with respect to overall survival in the second-line treatment of postmenopausal women with advanced breast carcinoma.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Antagonistsen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDouble-Blind Method-
dc.subject.meshEstradiol-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNitriles-
dc.subject.meshPostmenopause-
dc.subject.meshSurvival Analysis-
dc.subject.meshSurvival Rate-
dc.subject.meshTriazoles-
dc.titleFulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalCanceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.